Category: Case Study

As the pharmaceutical supply chain transitions into full compliance with the Drug Supply Chain Security Act (DSCSA), one issue that has been simmering below the surface for years is now starting to boil over: exception handling. While much of the

How a proactive trade response ensured same-day access to a critical rescue medication

The 2025 HDA Traceability Conference convened industry leaders, regulators, and supply chain experts to address the evolving landscape of DSCSA compliance. With enforcement now in full swing, the conference underscored the urgency of readiness, the complexity of operational alignment, and

After more than a decade of phased implementation, policy refinements, and grace periods, the Drug Supply Chain Security Act (DSCSA) has entered full enforcement mode. The FDA is no longer simply educating stakeholders — it is actively issuing Form 483

In preparing for the launch of a time-sensitive, temperature-sensitive therapy, a pharmaceutical manufacturer faced an exceptionally complex set of logistics and operational demands. The product required precise cold-chain handling, and the retail market expected delivery within a very

In the rare disease space, small and midsize manufacturers — typically generating between $100 million and $10 billion in annual revenue — are fueling much of today’s pharmaceutical innovation. These agile companies are often first to market with therapies targeting

A biopharmaceutical company was preparing for the commercial rollout of a novel therapy. With deep in-house scientific expertise but limited commercialization infrastructure, the company needed a strategic partner to guide it